Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK11 | Q15759 | 20/20 | 0.60 |
| ▸ | MAPK14 | Q16539 | 20/20 | 0.60 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.53 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12676759 | 0.83 | MAPK11 (0.65) | MAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL23591994 | 0.82 | HDAC1 (0.48) | MAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL23591988 | 0.82 | MAPK3 (0.56) | — | |
| SCHEMBL10090842 | 0.81 | MAPK11 (0.57) | MAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL1399816 | 0.81 | MAPK14 (0.53) | MAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL11965675 | 0.80 | MAPK14 (0.61) | MAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL243751 | 0.80 | MAPK11 (0.70) | MAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL3183420 | 0.80 | MAPK14 (0.61) | MAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL241982 | 0.80 | HDAC1 (0.68) | MAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL3314064 | 0.80 | MAPK14 (0.61) | MAPK11MAPK14MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2021133896-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | TEAD1, TEAD4, TEAD2 | MAPK11 2750/4885MAPK14 2780/4885MAPK13 3155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.